Histamine H3 receptor antagonists/ inverse agonists on cognitive and motor processes: Relevance to Alzheimer's disease, ADHD, schizophrenia and drug abuse

Frontiers in Systems Neuroscience

Volumn , Issue OCTOBER 2012, 2012, Pages 1-27

  Vohora, Divya ^a   Bhowmik, Malay ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

ADHD; Alzheimer's disease; Drug abuse; Histamine H3 receptor; Schizophrenia

Indexed keywords

5 (4 CYANOPHENYL) 2 [2 (2 METHYL 1 IMIDAZOLIDINYL)ETHYL]BENZOFURAN; ABT 288; ANTIHISTAMINIC AGENT; BF 2649; CIPROXIFAN; DONEPEZIL; DRUGS USED IN THE TREATMENT OF ADDICTION; GSK 239512; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; HISTAMINERGIC RECEPTOR AFFECTING AGENT; JNJ 10181457; JNJ 5207852; MK 0249; PF 03654746; PITOLISANT; PLACEBO; THIOPERAMIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN LEVEL; CONTINUOUS INFUSION; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG RESPONSE; HUMAN; NEUROPATHOLOGY; NONHUMAN; PROTEIN FUNCTION; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84867697955     PISSN: 16625137     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnsys.2012.00072     Document Type: Article

References (102)

1. Acevedo, S. F., and Raber, J. (2011). Histamine-dependent behavioral response to methamphetamine in 12-month-old male mice. Brain Res. 1993, 23-30.
2. Airaksinen, M.S., Paetau, A., Paljarvi, L., Reinikainen, K., Riekkinen, P., Suomalainen, R., and Panula, P. (1991). Histamine neurons in human hypothalamus: anatomy in normal and Alzheimer diseased brains. Neuroscience 44, 465-481.
3. Andersson, R., Lindskog, M., and Fisahn, A. (2010). Histamine H3 receptor activation decreases kainite-induced hippocampal gamma oscillations invito by action potential desynchronization in pyramidal neurons. J. Physiol. 588, 1241-1249.
4. Arrang, J. M., Devaux, B., Chodkiewicz, J. P., and Schwartz, J. C. (1988). H3 receptors control release of histamine in human brain. J. Neurochem. 51, 105-108.
5. Arrang, J. M., Garbarg, M., and Schwartz, J.C. (1983). Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 302, 832-837.
6. Bacciottini, L., Passani, M. B., Mannaioni, P. F., and Blandina, P. (2001). Interactions between histaminergic and cholinergic systems in learning and memory. Behav. Brain Res. 124, 183-194.
7. Bardgett, M. E., Davis, N. N., Schultheis, P. J., and Griffith, M. S. (2011). Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease. Neurobiol. Learn. Mem. 95, 64-72.
8. Bardgett, M. E., Points, M., Roflow, J., Blankenship, M., and Griffith, M. S. (2009). Effects of the H(3) antagonist, thioperamide, on behavioral alterations induced by systemic MK-801 administration in rats. Psychopharmacology 205, 589-597.
9. Bidwell, C. L., McClernon, F. J., and Kollins, S. H. (2011). Cognitive enhancers for the treatment of ADHD. Pharmacol. Biochem. Behav. 99, 262-274.
10. Bitner, R. S., Markosyan, S., Nikkel, A. L., and Brioni, J. D. (2011). In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease. Neuropharmacology 60, 460-466.
11. Bitner, R.S., Nikkel, A.L., Markosyan, S., Otte, S., Puttfarcken, P., and Gopalakrishnan, M. (2009). Selective alpha7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3beta and decreases tau phosphorylation in vivo. Brain Res. 1265, 65-74.
12. Bonaventure, P., Letavic, M., Dugovic, C, Wilson, S., Aluisio, L., Pudiak, C, Lord, B., Mazur, C, Kamme, F., Nishino, S., Carruthers, N, and Lovenberg, T. (2007). Histamine H3 receptor antagonists: From target identification to drug leads. Biochem. Pharmacol. 73, 1084-1096.
13. Braak, H, Braak, E., and Bohl, J. (1993). Staging of Alzheimer-related cortical destruction. Eur. Neurol. 33, 403-408.
14. Brabant, C, Alleva, L., Grisar, T., Quertemont, E., Lakaye, B., Ohtsu, H, Lin, J. S., Jatlow, P., Picciotto, M. R, and Tirelli, E. (2009). Effects of the H3 receptor.antagonist thioperamide on cocaine-induced locomotion in mice: role of the histaminergic system and potential pharmacokinetic interactions. Psychopharmacology 202, 673-687.
15. Brabant, C, Alleva, L., Quertemont, E., and Tirelli, E. (2010). Involvement of the brain histaminergic system in addiction and addiction-related behaviors: A comprehensive review with emphasis on the potential therapeutic use of histaminergic compounds in drug dependence. Prog. Neurobiol. 92, 421-424.
16. Brabant, C, Charlier, Y., Quertemont, E., and Tirelli, E. (2005). The H3 antagonist thioperamide reveals conditioned preference for a context associated with an inactive small dose of cocaine in C57BL/6J mice. Behav. Brain Res. 160, 161-168.
17. Brioni, J. D., Esbenshade, T. A., Garrison, T. R., Bitner, S. R., and Cowart, M. D. (2011). Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J. Pharmacol. Exp. Ther. 336: 38-46.
18. Bristow, L.J., and Bennett, G.W. (1988). A role for histamine H3 receptors in histamine induced hypoactivity in the rat. Br. J. Pharmacol. 94 (supplement), P319.
19. Brown, R. E., Stevens, D. R., and Haas, H. L. (2001). The physiology of brain histamine. Prog. Neurobiol. 63, 637-672.
20. Burban, A., Sadakhom, C., Dumoulin, D., Rose, C., LePen, G, Frances, H., and Arrang, J. M. (2010). Modulation of prepulse inhibition and stereotypies in rodents: no evidence for antipsychotic-like properties of histamine H3-receptor.antagonists. Psychopharmacology 210, 591-604.
21. Cacabelos, R., Fernández-Novoa, L., Pérez-Trullén, J. M., Franco-Maside, A., Alvarez, X. A. (1992). Serum histamine in Alzheimer's disease and multi-infarct dementia. Methods Find. Exp. Clin. Pharmacol. 14, 711-715.
22. Cacabelos, R, Yamatodani, A., Niigawa, H., Hariguchi, S., Tada, K., Nishimura, T., Wada, H., Brandeis, L., and Pearson, J. (1989). Brain histamine in Alzheimer's disease. Methods Find. Exp. Clin. Pharmacol. 11, 353-360.
23. Celik, E., Uzbay, T. I., and Karakas, S. (2006). Caffeine and amphetamine produce cross-sensitization to nicotine-induced locomotor activity in mice. Prog. Neuropsychopharmacol. Biol. Psychiatr. 30, 50-55.
24. Chen, P. Y., Tsai, C. T., Ou, C. Y., Hsu, W. T., Jhuo, M. D., Wu, C. H, Shih, T. C, Cheng, T. H, and Chung, J.G (2012). Computational analysis of novel drugs designed for use as acetylcholinesterase inhibitors and histamine H3 receptor antagonists for Alzheimer's disease by docking, scoring and de novo evolution. Mol. Med. Report. (Epub ahead of print).
25. Chiavegatto, S., Nasello, A., Bernardi, M. (1998) Histamine and spontaneous motor activity: biphasic changes, receptors involved and participation of the striataldopamine system. Life Sci. 62, 1875-1888.
26. Clapham, J., and Kilpatrick, G. J. (1994). Thioperamide, the selective histamine H3 receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse. Eur. J. Pharmacol. 259, 107-114.
27. Coyle, J. T., Price, D. L., and DeLong, M. R. (1983). Cortese, S. (2012). The neurobiology and genetics of attention-deficit hyperactivity disorder (ADHD): what every clinician should know. Eur. J. Paediatr. Neurol. 1-12 (Epub ahead of print).
28. Alzheimer's disease: a disorder of central cholinergic innervation. Science 219, 1184-1190.
29. Curatolo, P., Paloscia, C., D'Agati, E., Moavero, R., and Pasini, A. (2009). The neurobiology of attention deficit/hyperactivity disorder. Eur. J. Paediatr. Neurol. 13, 299-304.
30. Dai, H., Okuda, H., Iwabuchi, K., Sakurai, E., Chen, Z., Kato, M., Iinuma, K., and Yanai, K. (2004). Social isolation stress significantly enhanced the disruption of prepulse inhibition in mice repeatedly treated with methamphetamine. Ann. N. Y. Acad. Sci. 1025, 257-266.
31. Day, M., Pan, J. B., Buckley, M. J., Cronin, E., Hollingsworth, P. R., Hirst, W. D., Navarra, R., Sullivan, J. P., Decker, M. W., and Fox, G. B. (2007). Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test. Biochem. Pharmacol. 73, 1123-1134.
32. Deng, C., Weston-Green, K., and Huang, X. F. (2010).The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 1-4.
33. Drahl, C. (2009). Curtain rises on potential drugs. ACS meeting news: medicinal chemists disclose candidates for treating neurological, metabolic, and other disorders. Chem. Eng. News 87, 31-33.
34. Fernandez-Novoa, L., and Cacabelos, R. (2001). Histamine function in brain disorders. Behav. Brain. Res. 124, 213-233.
35. Fernandez-Novoa, L., Corzo, L., Zas, R., Alvarez, X. A., Cacabelos, R. (1997). Global Deterioration Scale-related brain hemodynamics and histamine levels in Alzheimer's disease and vascular dementia. Ann. N. Y. Acad. Sci. 826, 396-400.
36. Ferrada, C., Ferré, S., Casado, V., Cortés, A., Justinova, Z., Barnes, C., Canela, E. I., Goldberg, S. R., Leurs, R., Lluis, C., and Franco, R. (2008). Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology 55, 190-197.
37. Ferrada, C., Moreno, E., Casado, V., Bongers, G., Cortes, A., Mallol, J., Canela, E. I., Leurs, R., Ferre, S., Lluis, C., and Franco, R. (2009). Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3receptors. Br. J. Pharmacol.157, 64-75.
38. Flik, G., Dremencov, E., Cremers, T. I., Folgering, J. H., and Westerink, B. H. (2011). The role of cortical and hypothalamic histamine-3 receptors in the modulation of central histamine neurotransmission: an in vivo electrophysiology and microdialysis study. Eur. J. Neurosci. 34, 1747-1755.
39. Fox, G. B., Esbenshade, T. A., Pan, J. B., Radek, R. J., Krueger, K. M., Yao, B. B., Browman, K. E., Buckley, M. J., Ballard, M. E., Komater, V. A., Miner, H., Zhang, M., Faghih, R., Rueter, L. E., Bitner, R. S., Drescher, K. U., Wetter, J., Marsh, K., Lemaire, M., Porsolt, R. D., Bennani, Y. L., Sullivan, J. P., Cowart, M. D., Decker, M. W., and Hancock, A. A. (2005). Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl] ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J. Pharmacol. Exp. Ther. 313, 176-190.
40. Fox, G. B., Pan, J. B., Esbenshade, T. A., Bennani, Y. L., Black, L. A., Faghih, R., Hancock, A. A., and Decker, M. W. (2002). Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav. Brain Res. 131, 151-161.
41. Fu, Q., Dai, H, He, P., Hu, W., Fan, Y., Zhang, W., and Chen, Z. (2010). The H3 receptor antagonist clobenpropit protects against Abeta42-induced neurotoxicity in differentiated rat PC12 cells. Pharmazie 65, 257-260.
42. Galici, R, Rezvani, A., Aluisio, L., Lord, B., Levin, E. D., Fraser, I, Boggs, J., Welty, N., Shoblock, J. R., Motley, S. T., Letavic, M. A., Carruthers, M. I., Dugovic, C, Lovenberg, T. W., Bonaventure, P. (2011). JNJ-39220675, a novel histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacol. 214, 829-841.
43. Giacobini, E., and Becker, R. E. (2007). One hundred years after the discovery of Alzheimer's disease. A turning point for therapy? J. Alzheimers Dis. 12, 37-52.
44. Giannoni, P., Medhurst, A. D., Passani, M. B., Giovannini, M. G, Ballini, C, Corte, L. D., and Blandina, P. (2010). Regional differential effects of the novel histamine H3 receptor antagonist6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1 H-3-benzazepin-7-yl)oxy]-N methyl-3-pyridinecarboxamide hydrochloride (GSK189254) on histamine release in the central nervous system of freely moving rats. J. Pharmacol. Exp. Ther. 332, 164-172.
45. Gemkow, M. J., Davenport, A. J., Harich, S., Ellenbroek, B. A., Cesura, A., and Hallett, D. (2009). The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov. Today 14, 509-515.
46. Goodman, A. (2008). The neurobiology of addiction: An integrated review. Biochem. Pharmacol. 75, 266-322.
47. Goto, Y., Lee, Y. A. (2011). The effects of histamine H3 antagonist in the animal model of ADHD with neonatal habenula lesion. Neurosci. Res. 71S, e402.
48. Gross, G., and Huber, G (2008). Psychopathology of schizophrenia and brain imaging. Fortschr. Neurol. Psychiatr. 76, S49-S56.
49. Haas, H. and Panula, P. (2003). The role of histamine and the tuberomamillary nucleus in the nervous system. Nat. Rev. Neurosci. 4, 121-130.
50. Haas, H. L., Sergeeva, O. A., and Selbach, O. (2008). Histamine in the nervous system. Physiol. Rev. 88, 1183-1241.
51. Hajos, M., Siok, C. J., Hoffmann, W. E., Li, S., and Kocsis, B. (2008). Modulation of hippocampal theta oscillation by histamine H3 receptors. J. Pharmacol. Exp. Ther. 324, 391-398.
52. Hooper, C, Killick, R, and Lovestone, S. (2008). The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 104, 1433-1439.
53. Ibrahim, H. M., and Tamminga, C. A. (2012). Treatment of cognitive dysfunction in schizophrenia. Curr. Pharm. Biotechnol. [Epub ahead of print].
54. Ito, C. (2009). Histamine H3-receptor.antagonists as novel antipsychotics. Cent. Nerv. Syst. Agents Med. Chem. 9, 132-136.
55. Ito, C, Onodera, K., Sakurai, E., Sato, M., and Watanabe, T. (1996). The effect of methamphetamine on histamine level and histidine decarboxylase activity in the rat brain. Brain Res. 734, 98-102.
56. Ito, C, Onodera, K., Sakurai, E., Sato, M., Watanabe, T., (1997). Effect of cocaine on the histaminergic neuron system in the rat brain. J. Neurochem. 69, 875-878.
57. Jin, C. Y., Anichtchik, O., and Panula, P. (2009). Altered histamine H3 receptor radioligand binding in post-mortem brain samples from subjects with psychiatric diseases. Br. J. Pharmacol. 157, 118-129.
58. Komater, V. A., Browman, K. E., Curzon, P., Hancock, A. A., Decker, M. W., and Fox, G. B. (2003). H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization. Psychopharmacology (Berl.) 167: 363-372.
59. Kuhne, S., Wijtmans, M., Lim, H. D., Leurs, R., and de Esch, I. J. (2011). Several down, a few to go: histamine H3 receptor ligands making the final push towards the market? Expert Opin. Investig. Drugs 20, 1629-1648.
60. Lazewska, D., and Kiec-Kononowicz, K. (2010). Recent advances in histamine H3 receptor antagonists/antagonists. Expert Opin. Ther. Pat. 20, 1147-1169.
61. Leurs, R., Bakker, R. A., Timmerman, H, de Esch, I. J. (2005). The histamine H3 receptor: From gene cloning to H3 receptor drugs. Nature Rev. Drug Discovery 4, 107-122.
62. Leurs, R, Vischer, H. F., Wijtmans, M., and de Esch, I. J. (2011). En route to new blockbuster anti-histamines: surveying the offspring of the expanding histamine receptor family. Trends Pharmacol. Sci. 32, 250-257.
63. Levin, E. D., Slade, S., Wells, C, Pruitt, M., Cousins, V., Cauley, M., Petro, A., Hampton, D., and Rose, J. (2011). Histamine H1 antagonist treatment with pyrilamine reduces nicotine self-administration in rats. Eur. J. Pharmacol. 650, 256-260.
64. Ligneau, X., Landais, L., Perrin, D., Piriou, J., Uguen, M., Denis, E., Robert, P., Parmentier, R, Anaclet, C, Lin, J. S., Burban, A., Arrang, J. M., and Schwartz, J. C. (2007). Brain histamine and schizophrenia: Potential therapeutic applications of H3-receptor.antagonists studied with BF2.649. Biochem. Pharmacol. 73, 1215-1224.
65. Lintunen, M., Hyytia, P., Sallmen, T., Karlstedt, K., Tuomisto, L., Leurs, R., Kiianmaa, K., Korpi, E. R., and Panula, P. (2001). Increased brain histamine in an alcohol-preferring rat line and modulation of ethanol consumption by H3 receptor mechanisms. FASEB J. 15, 1074-1076.
66. Lovenberg, T. W., Roland, B. L., Wilson, S. J., Jiang, X., Pyati, J., Huvar, A., Jackson, M. R., and Erlander, M. G. (1999). Cloning and functional expression of the human histamine H3 receptor. Mol. Pharmacol. 55, 1101-1107.
67. Martin, L., Latypova, X., and Terro, F. (2011). Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem. Int. 58, 458-471.
68. Mazurkiewicz-Kwilecki, I.M., and Nsonwah, S. (1989). Changes in the regional brain histamine and histidine levels in postmortem brains of Alzheimer patients. Can. J. Physiol. Pharmacol. 67, 75-78.
69. Medhurst, A. D., Atkins, A. R., Beresford, I. J., Brackenborough, K., Briggs, M. A., Calver, A. R., Cilia, J., Cluderay, J. E., Crook, B., Davis, J. B., Davis, R. K., Davis, R. P., Dawson, L. A., Foley, A. G., Gartlon, J., Gonzalez, M. I, Heslop, T., Hirst, W. D., Jennings, C, Jones, D. N., Lacroix, L. P., Martyn, A., Ociepka, S., Ray, A., Regan, C. M., Roberts, J. C, Schogger, J., Southam, E., Stean, T. O., Trail, B. K., Upton, N., Wadsworth, G, Wald, J. A., White, T., Witherington, J., Woolley, M. L., Worby, A., and Wilson, D. M. (2007). GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J. Pharmacol. Exp. Ther. 321, 1032-1045.
70. Medhurst A. D., Roberts, J. C, Lee, J., Chen, C. P., Brown, S. H, Roman, S., Lai, M. K. (2009). Characterization of histamine H3 receptors in Alzheimer's Disease brain and amyloid over-expressing TASTPM mice. Br. J. Pharmacol. 157: 130-138.
71. Morisset, S., Pilon, C, Tardivel-Lacombe, J., Weinstein, D., Rostene, W., Betancur, C, Sokoloff, P., Schwartz, J. C, and Arrang JM. (2002) Acute and chronic effects of methamphetamine on tele-methylhistamine levels in mouse brain: selective involvement of the D(2) and not D(3) receptor. J. Pharmacol. Exp. Ther. 300, 621-628.
72. Motawaj, M., and Arrang, J. M. (2011). Ciproxifan, a histamine H3-receptor antagonist/.antagonist modulates methamphetamine-induced sensitization in mice. Eur. J. Neurosci. 33, 1197-1204.
73. Motawaj, M., Burban, A., Davenas, E., and Arrang, J. M. (2011). Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer's disease. J. Pharmacol. Exp. Ther. 336, 479-487.
74. Munzar, P., Tanda, G, Justinova, Z., and Goldberg, S. (2004). Histamine H3 receptor antagonists potentiate methamphetamine self-administration and methamphetamine- induced accumbal dopamine release. Neuropsychopharmacology 29, 705-717.
75. Nakamura, S., Takemura, M., Ohnishi, K., Suenaga, T., Nishimura, M., Akiguchi, I., Kimura, J., and Kimura, T. (1993). Loss of large neurons and occurrence of neurofibrillary tangles in the tuberomammillary nucleus of patients with Alzheimer's disease. Neurosci. Lett. 151, 196-199.
76. Nestler, E. J. (2005). Is there a common molecular pathway for addiction? Nature Neurosci. 8, 1445-1449.
77. Nishibori, M., Oishi, R, Itoh, Y., Saeki, K (1985). Morphine-induced changes in histamine dynamics in the brain. J Neurochem. 45, 719-724.
78. Nuutinen, S., and Panula, P. (2010). Histamine in neurotransmission and brain diseases. Adv. Exp. Med. Biol.709, 95-107.
79. Nuutinen, S., Karlstedt, K., Aitta-Aho, T., Korpi, E.R., and Panula, P. (2010). Histamine and H3 receptor-dependent mechanisms regulate ethanol stimulation and conditioned place preference in mice. Psychopharmacology 208, 75-86.
80. Nuutinen, S., Vanhanen, J., Pigni, M. C, and Panula, P. (2011). Effects of histamine H3 receptor ligands on the rewarding, stimulant and motor-impairing effects of ethanol in DBA/2J mice. Neuropharmacology 60, 1193-1199.
81. Okuda, T., Ito, Y., Nakagawa, N, Hishinuma, T., Tsukamoto, H, Iwabuchi, K., Watanabe, T., Kitaichi, K., Goto, J., and Yanai, K. (2004). Drug interaction between methamphetamine and antihistamines: behavioral changes and tissue concentrations of methamphetamine in rats. Eur. J. Pharmacol. 505, 135-144.
82. Panula, P., Rinne, J., Kuokkanen, K., Eriksson, K.S., Sallmen, T., Kalimo, H., and Relja, M. (1998). Neuronal histamine deficit in Alzheimer's disease. Neuroscience 82, 993-997.
83. Passani, M. B., and Blandina, P. (2011). Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol. Sci. 32, 242-249.
84. Passani, M. B., Lin, J. S., Hancock, A., Crochet, S., and Blandina, P. (2004). The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorder. Trends Pharmacol. Sci. 25, 618-625.
85. Pillot, C, Heron, A., Cochois, V., Tardivel-Lacombe, J., Ligneau, X., Schwartz, J. C, and Arrang, J. M. (2002a). A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain. Neuroscience 114, 173-193.
86. Pillot, C, Heron, A., Schwartz, J. C, and Arrang, J. M. (2003). Ciproxifan, a histamine H3-receptor antagonist/antagonist modulates the effects of methamphetamine on neuropeptide mRNA expression in rat striatum. Eur. J. Neurosci. 17, 307-314.
87. Pillot, C, Ortiz, J., Heron, A., Ridray, S., Schwartz, J. C, and Arrang, J. M. (2002b). Ciproxifan, a histamine H3-receptor antagonist/antagonist, potentiates neurochemical and behavioral effects of haloperidol in the rat. J. Neurosci. 22, 7272-7280.
88. Pollard, H, Moreau, J., Arrang, J., and Schwartz, J. (1993). A detailed autoradiographic mapping of histamine H3 receptors in rat brain areas. Neuroscience 52, 169-189.
89. Potenza, M. N, Sofuoglu, M., Carroll, K. M., and Rounsaville, B. J. (2011). Neuroscience of behavioral and pharmacological treatments for addictions. Neuron 69, 695-712.
90. Raddatz, R., Hudkins, R L., Mathiasen, J. R, Gruner, J. A., Flood, D. G., Aimone, L. D., Le, S., Schaffhauser, H., Duzic, E., Gasior, M., Bozyczko-Coyne, D., Marino, M. J., Ator, M. A., Bacon, E. R., Mallamo, J. P., and Williams, M. (2012). CEP-26401 (irdabisant), a potent and selective histamine H3 receptor antagonist/antagonist with cognition-enhancing and wake-promoting activities. J. Pharmacol. Exp. Ther. 340, 124-133.
91. Sander, K., Kottke, T., and Stark, H. (2008). Histamine H3 receptor antagonists go to clinics. Biol. Pharm. Bull. 31, 2163-2281.
92. Saper, C. B., and German, D. C. (1987). Hypothalamic pathology in Alzheimer's disease. Neurosci. Lett. 74, 364-370.
93. Schwartz, J. C. (2011). The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br. J. Pharmacol. 163, 713-721.
94. Shan L, Bossers K, Unmehopa U, Bao AM, Swaab DF (2012). Alterations in the histaminergic system in Alzheimer's disease: a postmortem study. Neurobiol. Aging [Epub ahead of print].
95. Shin, Y. W., O'Donnell, B. F., Youn, S., and Kwon, J. S. (2011). Gamma oscillation in schizophrenia. Psychiatry Investig. 8, 288-296.
96. Southam, E., Cilia, J., Gartlon, J. E., Woolley, M. L., Lacroix, L. P., Jennings, C. A., Cluderay, J. E., Reavill, C, Rourke, C, Wilson, D. M., Dawson, L. A., Medhurst, A. D., and Jones, D. N. (2009). Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040. Psychopharmacology 201, 483-494.
97. Tiligada, E., Zampeli, E., Sander, K., and Stark, H. (2009). Histamine H3 and H4 receptors as novel drug targets. Expert Opin. Investig. Drugs 18, 1519-1531.
98. Trujillo, K. A., Kubota, K. S., Warmoth, K. P. (2004). Continuous administration of opioids produces locomotor sensitization. Pharmacol. Biochem. Behav. 79, 661-669.
99. Viggiano, D. (2008). The hyperactive syndrome: metaanalysis of genetic alterations, pharmacological treatments and brain lesions which increase locomotor activity. Behav. Brain Res. 194, 1-14.
100. Weisler, R. H., Pandina, G. J., Daly, E. J., Cooper, K., and Gassmann-Mayer, C. (2012). Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs 26, 421-434.
101. Whitehouse, P. J., Price, D. L., Struble, R. G, Clark, A. W., Coyle, J. T., and Delon, M. R (1982). Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215: 1237-1239.
102. Zimatkin, S. M., Anichtchik, O. V. (1999). Alcohol-histamine interactions. Alcohol Alcohol 34, 141-147.